SEC FIlings Archives - Scilex Holding

19 Apr

SEC FIlings

Notice of Effectiveness

April 20, 2023
Posted by Ulisses

19 Apr

SEC FIlings

Prospectus [Rule 424(b)(3)]

April 19, 2023
Posted by Ulisses

17 Apr

SEC FIlings

Additional definitive proxy soliciting materials and Rule 14(a)(12)

April 17, 2023
Posted by Ulisses

11 Apr

SEC FIlings

Prospectus [Rule 424(b)(3)]

April 11, 2023
Posted by Ulisses

11 Apr

SEC FIlings

Prospectus [Rule 424(b)(3)]

April 11, 2023
Posted by Ulisses

11 Apr

SEC FIlings

Prospectus [Rule 424(b)(3)]

April 11, 2023
Posted by Ulisses

11 Apr

SEC FIlings

Current report

April 11, 2023
Posted by Ulisses

10 Apr

SEC FIlings

General form for registration of securities under the Securities Act of 1933

April 10, 2023
Posted by Jitendra

05 Apr

SEC FIlings

Additional definitive proxy soliciting materials and Rule 14(a)(12)

April 5, 2023
Posted by Jitendra

03 Apr

SEC FIlings

Current report

April 3, 2023
Posted by Jitendra

SEC FIlings

Notice of Effectiveness

Prospectus [Rule 424(b)(3)]

Additional definitive proxy soliciting materials and Rule 14(a)(12)

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Current report

General form for registration of securities under the Securities Act of 1933

Additional definitive proxy soliciting materials and Rule 14(a)(12)

Current report

test according

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists